393 related articles for article (PubMed ID: 21793951)
1. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus.
Urbonaviciute V; Voll RE
J Intern Med; 2011 Oct; 270(4):309-18. PubMed ID: 21793951
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus.
Urbonaviciute V; Starke C; Pirschel W; Pohle S; Frey S; Daniel C; Amann K; Schett G; Herrmann M; Voll RE
Arthritis Rheum; 2013 Jun; 65(6):1612-23. PubMed ID: 23450347
[TBL] [Abstract][Full Text] [Related]
3. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.
Bobek D; Grčević D; Kovačić N; Lukić IK; Jelušić M
Pediatr Rheumatol Online J; 2014; 12():50. PubMed ID: 25516724
[TBL] [Abstract][Full Text] [Related]
4. Extracellular, but not intracellular HMGB1, facilitates self-DNA induced macrophage activation via promoting DNA accumulation in endosomes and contributes to the pathogenesis of lupus nephritis.
Li X; Yue Y; Zhu Y; Xiong S
Mol Immunol; 2015 May; 65(1):177-88. PubMed ID: 25660970
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus.
Means TK; Luster AD
Ann N Y Acad Sci; 2005 Dec; 1062():242-51. PubMed ID: 16461805
[TBL] [Abstract][Full Text] [Related]
6. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies.
Musumeci D; Roviello GN; Montesarchio D
Pharmacol Ther; 2014 Mar; 141(3):347-57. PubMed ID: 24220159
[TBL] [Abstract][Full Text] [Related]
7. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE.
Urbonaviciute V; Fürnrohr BG; Meister S; Munoz L; Heyder P; De Marchis F; Bianchi ME; Kirschning C; Wagner H; Manfredi AA; Kalden JR; Schett G; Rovere-Querini P; Herrmann M; Voll RE
J Exp Med; 2008 Dec; 205(13):3007-18. PubMed ID: 19064698
[TBL] [Abstract][Full Text] [Related]
8. Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway.
Wen Z; Xu L; Chen X; Xu W; Yin Z; Gao X; Xiong S
J Immunol; 2013 Jun; 190(11):5411-22. PubMed ID: 23616573
[TBL] [Abstract][Full Text] [Related]
9. High-mobility group box-1 in ischemia-reperfusion injury of the heart.
Andrassy M; Volz HC; Igwe JC; Funke B; Eichberger SN; Kaya Z; Buss S; Autschbach F; Pleger ST; Lukic IK; Bea F; Hardt SE; Humpert PM; Bianchi ME; Mairbäurl H; Nawroth PP; Remppis A; Katus HA; Bierhaus A
Circulation; 2008 Jun; 117(25):3216-26. PubMed ID: 18574060
[TBL] [Abstract][Full Text] [Related]
10. High mobility group box 1 promotes small intestinal damage induced by nonsteroidal anti-inflammatory drugs through Toll-like receptor 4.
Nadatani Y; Watanabe T; Tanigawa T; Machida H; Okazaki H; Yamagami H; Watanabe K; Tominaga K; Fujiwara Y; Arakawa T
Am J Pathol; 2012 Jul; 181(1):98-110. PubMed ID: 22634181
[TBL] [Abstract][Full Text] [Related]
11. Transgenic overexpression of anti-double-stranded DNA autoantibody and activation of Toll-like receptor 4 in mice induce severe systemic lupus erythematosus syndromes.
Lee TP; Tang SJ; Wu MF; Song YC; Yu CL; Sun KH
J Autoimmun; 2010 Dec; 35(4):358-67. PubMed ID: 20833510
[TBL] [Abstract][Full Text] [Related]
12. HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development.
Abdulahad DA; Westra J; Limburg PC; Kallenberg CG; Bijl M
Autoimmun Rev; 2010 Aug; 9(10):661-5. PubMed ID: 20546955
[TBL] [Abstract][Full Text] [Related]
13. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process.
Papadimitraki ED; Choulaki C; Koutala E; Bertsias G; Tsatsanis C; Gergianaki I; Raptopoulou A; Kritikos HD; Mamalaki C; Sidiropoulos P; Boumpas DT
Arthritis Rheum; 2006 Nov; 54(11):3601-11. PubMed ID: 17075805
[TBL] [Abstract][Full Text] [Related]
14. Systemic involvement of high-mobility group box 1 protein and therapeutic effect of anti-high-mobility group box 1 protein antibody in a rat model of crush injury.
Shimazaki J; Matsumoto N; Ogura H; Muroya T; Kuwagata Y; Nakagawa J; Yamakawa K; Hosotsubo H; Imamura Y; Shimazu T
Shock; 2012 Jun; 37(6):634-8. PubMed ID: 22392147
[TBL] [Abstract][Full Text] [Related]
15. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus.
Barrat FJ; Meeker T; Gregorio J; Chan JH; Uematsu S; Akira S; Chang B; Duramad O; Coffman RL
J Exp Med; 2005 Oct; 202(8):1131-9. PubMed ID: 16230478
[TBL] [Abstract][Full Text] [Related]
16. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).
van Beijnum JR; Buurman WA; Griffioen AW
Angiogenesis; 2008; 11(1):91-9. PubMed ID: 18264787
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury.
Qing X; Pitashny M; Thomas DB; Barrat FJ; Hogarth MP; Putterman C
Immunol Lett; 2008 Nov; 121(1):61-73. PubMed ID: 18822317
[TBL] [Abstract][Full Text] [Related]
18. Dealing with death: HMGB1 as a novel target for cancer therapy.
Lotze MT; DeMarco RA
Curr Opin Investig Drugs; 2003 Dec; 4(12):1405-9. PubMed ID: 14763124
[TBL] [Abstract][Full Text] [Related]
19. Autoimmunity against nucleosomes and lupus nephritis.
Van Bruggen MC; Kramers C; Berden JH
Ann Med Interne (Paris); 1996; 147(7):485-9. PubMed ID: 9092359
[TBL] [Abstract][Full Text] [Related]
20. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus.
Li J; Xie H; Wen T; Liu H; Zhu W; Chen X
J Rheumatol; 2010 Apr; 37(4):766-75. PubMed ID: 20110525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
